Skip to main content
SpringerLink
Log in
Book cover

Renal Anemia pp 37–47Cite as

When does anemia impact the heart in chronic kidney disease?

  • Chapter

  • 112 Accesses

Abstract

It is well documented that patients with kidney disease have a high burden of cardiovascular illness. CVD can be simplistically categorized into disorders of perfusion and disorders of pump function [1]. Both can coexist, and one can exacerbate the other. Importantly, disorders of perfusion may well be due to atherosclerotic processes, while disorders of pump function can be due to ischemic damage (the result of perfusion disorders), but are also related to abnormalities of left ventricular geometry and growth, which may be propagated by specific components present in uremic milieu. Using a similar dichotomous approach, risk factors for cardiovascular disease (CVD) in patients with kidney disease can be categorized into both “traditional” and “uremia-related”, which would correspond to those factors impacting vasculature (perfusion) and those impacting pump function.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Parfrey P. Is renal insufficiency an atherogenic state? Reflections on prevalence, incidence and risk. Am J Kidney Dis. 2001;37:154–7.

    Article  PubMed  CAS  Google Scholar 

  2. Foley RN, Parfrey PS, Harnett JD, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47:186–92.

    Article  PubMed  CAS  Google Scholar 

  3. European Survey on Anemia Management (ESAM) Nephrol Dial Transplantation. 2000;15(supplement 4).

    Google Scholar 

  4. USRDS: Annual Data Report V. Patient mortality and survival. Am J Kidney Dis. 1998;32(supplement 1): S69–S80.

    Article  Google Scholar 

  5. United States Renal Data System. USRDS 1998 Annual Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1998.

    Google Scholar 

  6. Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplantation. 1996;11:1277–85.

    CAS  Google Scholar 

  7. Rigatto C, Foley R, Kent G, et al. Long term changes in left ventricular hypertrophy following renal transplantation. Transplantation. 2000;70:570–5.

    Article  PubMed  CAS  Google Scholar 

  8. Levin A, Djurdjev O, Barrett B, Burgess E, et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis. 2001;38:1398–407

    Article  PubMed  CAS  Google Scholar 

  9. Hemmelgarn BC, Ghali WAS, Quan HB, et al. for the APPROACH investigators. Poor long term survival after coronary angiogram in patients with renal insufficiency. Am J Kidney Dis. 2001;37:64–72.

    Article  PubMed  CAS  Google Scholar 

  10. Beattie JN, Soman SS, Sandberg KR, Yee J, Borzak S, McCullough PA. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis. 2001;37:1191–200.

    Article  PubMed  CAS  Google Scholar 

  11. Mann J, Gertstein, HC, Pogue J, Baosch, Yusef, S for the Hope Investigators. Renal insufficiency as a predictor cardiovascular outcomes and the impact of ramipril: The Hope Randomized Trial. Ann Intern Med. 2001;134(8):629–36.

    Article  PubMed  CAS  Google Scholar 

  12. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998;11:239–45.

    PubMed  CAS  Google Scholar 

  13. Greaves SC, Gamble GD, Collins JF, Whalley GA, Sharpe DN. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am J Kidney Dis. 1994;24:768–76.

    PubMed  CAS  Google Scholar 

  14. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis. 1996;27:347–54.

    Article  PubMed  CAS  Google Scholar 

  15. Levin A, Thompson C, Either J, Carlisle E, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis. 1999;34: 125–34.

    Article  PubMed  CAS  Google Scholar 

  16. Parfrey PS, Harnett JD, Foley RN. Heart failure and ischemic heart disease in chronic uremia. Curr Opin Nephrol Hypertens. 1995;4:105–10.

    Article  PubMed  CAS  Google Scholar 

  17. Harnett JD, Kent GM, Foley RN, Parfrey PS. Cardiac function and hematocrit level. Am J Kidney Dis. 1995;25:S3-S7.

    Article  PubMed  CAS  Google Scholar 

  18. Holland DC, Lam M. Predictors of hospitalization and death among pre-dialysis patients: a retrospective cohort study. Nephrol Dial Transplantation. 2000;15: 650–8.

    Article  CAS  Google Scholar 

  19. Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis. 1998;32:S133–S141.

    Article  PubMed  CAS  Google Scholar 

  20. Rigatto C. Cardiac disease in renal transplant recipients. Masters theses, Memorial University Department of Epidemiology, June 2001.

    Google Scholar 

  21. Foley RN, Parfrey PS, Morgan J, Barre P, Campbell P, Cartier P, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–35.

    Article  PubMed  CAS  Google Scholar 

  22. Besarab A, Bolton W, Browne J, Egrie J, Nissenson A, Okamoto D, Schwab S, Goodkin D. The effects of normal as compared with low hematocrit values in patients with cardiac disease receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–90.

    Article  PubMed  CAS  Google Scholar 

  23. Hayashi T, Suzuki A, Shoji T, Togawa M, Okada N, Tsubakihara Y, Imai E, Hori M. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis. 2000; 35:250–6.

    Article  PubMed  CAS  Google Scholar 

  24. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–85.

    Article  PubMed  CAS  Google Scholar 

  25. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero J, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in pre-dialysis patients. Am J Kidney Dis. 1997;29:541–8.

    Article  PubMed  CAS  Google Scholar 

  26. Hunter JJ, Chien KR. Signalling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999;341:1276–83.

    Article  PubMed  CAS  Google Scholar 

  27. Amann K, Kronenberg G, Gehlen F, et al. Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplantation. 1998;13:1958–66.

    Article  CAS  Google Scholar 

  28. London GM, Fabiani F, Marchais SJ, et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int. 1987;31:973–80.

    Article  PubMed  CAS  Google Scholar 

  29. Middleton, Rachel J, Parfrey P, Foley R. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001;12:1079–84.

    PubMed  CAS  Google Scholar 

  30. Eckardt KU. Cardiovascular consequences of renal anaemia and erythropoietin therapy. Nephrol Dial Transplantation. 1999;14:1317–23.

    Article  CAS  Google Scholar 

  31. Murphy SW, Foley RN, Barrett BJ, et al. Comparative hospitalization of hemodialysis and peritoneal dialysis patients in canada. Kidney Int. 2000;57: 2557–63.

    Article  PubMed  CAS  Google Scholar 

  32. Silverberg D, Wexler D, Blum M, Keren G, Sheps D, Laibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–44.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Adeera Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Inpatient Dialysis Services, SUNY Downstate Medical Center, Brooklyn, New York, USA

    Onyekachi Ifudu (Associate Professor of Medicine, Director) (Associate Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Levin, A. (2002). When does anemia impact the heart in chronic kidney disease?. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9998-6_5

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6045-7

  • Online ISBN: 978-94-015-9998-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation